Marshall Wace LLP boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 85.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 954,294 shares of the medical research company's stock after buying an additional 439,649 shares during the period. Marshall Wace LLP owned approximately 0.53% of IQVIA worth $187,528,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. NFJ Investment Group LLC increased its position in IQVIA by 20.5% during the 4th quarter. NFJ Investment Group LLC now owns 36,893 shares of the medical research company's stock worth $7,250,000 after purchasing an additional 6,282 shares in the last quarter. Guggenheim Capital LLC boosted its position in IQVIA by 5.3% during the fourth quarter. Guggenheim Capital LLC now owns 22,552 shares of the medical research company's stock valued at $4,432,000 after acquiring an additional 1,140 shares during the last quarter. Canada Post Corp Registered Pension Plan acquired a new stake in IQVIA during the fourth quarter worth approximately $572,000. Stamos Capital Partners L.P. acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $1,490,000. Finally, Sagespring Wealth Partners LLC bought a new stake in IQVIA in the fourth quarter valued at $913,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.
IQVIA Price Performance
Shares of IQV stock traded down $4.78 on Friday, reaching $143.66. The company's stock had a trading volume of 3,302,597 shares, compared to its average volume of 1,406,157. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The stock's 50 day simple moving average is $176.42 and its 200-day simple moving average is $196.86. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a PEG ratio of 1.99 and a beta of 1.46.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Analysts Set New Price Targets
IQV has been the subject of a number of research analyst reports. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Morgan Stanley boosted their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a report on Friday, February 7th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Mizuho dropped their target price on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $241.50.
View Our Latest Report on IQV
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
